Life Sciences

The transition towards more personalized treatments and the end of the single blockbuster drug era mean that all actors within pharma and health technology sectors are facing rapidly increasing legal complexity. Our team works closely with various national and international life sciences companies, providing advisory on matters varying from regulatory hurdles to complex transactions. In addition, members of our team are regularly involved in the strategy work relating to and drafting of new initiatives in the sector.

Main contacts